Rituxan is indicated for the treatment of pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL)...
Tell your healthcare provider right away if you have chest pain or irregular heartbeats during treatment with Rituxan Kidney Problems: especially if you are receiving Rituxan for non–Hodgkin’s lymphoma (NHL). Rituxan can cause severe kidney problems that lead to death. Your healthcare provider...
Learn about RITUXAN® (rituximab) treatment for rheumatoid arthritis (RA) patients including efficacy, safety, MOA and dosing. Please see Important Safety Information including Boxed Warning and Full Prescribing Information for more information.
Tell your healthcare provider right away if you have chest pain or irregular heartbeats during treatment with Rituxan Kidney Problems: especially if you are receiving Rituxan for non–Hodgkin’s lymphoma (NHL). Rituxan can cause severe kidney problems that lead to death. Your healthcare provider...
Learn about RITUXAN® (rituximab) treatment for rheumatoid arthritis (RA) patients including efficacy, safety, MOA and dosing. Please see Important Safety Information including Boxed Warning and Full Prescribing Information for more information.
Hepatitis B Virus (HBV) Reactivation:Before you receive your Rituxan treatment, your healthcare provider will do blood tests to check for HBV infection. If you have had hepatitis B or are a carrier of hepatitis B virus, receiving Rituxan could cause the virus to become an active infection aga...
In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long the...
[1] FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma. Retrieved November 28, 2018, from fda.gov/NewsEvents/News [2] Rituxan. Retrieved November 28, 2018, from rituxan.com/ [3] Biosimilar Product Information. Retrieved November 28, 2018, from fda.gov...
Follicular Lymphoma as a single agent follow-up therapy for patients who did not progress on initial treatment with CVP chemotherapy Diffuse Large B-Cell Lymphoma (DLBCL) as an initial treatment in combination with CHOP or other anthracycline-based chemotherapy regimens ...
During its first decade of use (1993鈥3), rituximab has had an important impact on treatment strategies for lymphoma and other hematologic malignancies. During the 5 years following approval, its applications expanded beyond non-Hodgkin鈥檚 lymphoma to a variety of malignant and non-malignant B-...